MultiBiotic™

Product description

MultiBiotic™ is an evidence-based multi-species probiotic specifically designed to target end-organ function and support gastrointestinal health and maintenance. MultiBiotic™ is an ARTG listed medicine and available in Pharmacies and HCP's in AU, NZ, SG and HK. Presently MultiBiotic™ is in Phase 1 clinical trials for chemotherapy induced mucositis and neutropenia. It is listed on the Australian New Zealand Clinical Trials Registry: ACTRN12618000927224

CLINICAL TRIAL: The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea: an exploratory end-point pilot study. ANZCTR: ACTRN12618000927224KEY

PUBLICATIONS: Thomsen M, Clarke S, Vitetta L 2018. The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. Article in Press, Beneficial Microbes, 2018 online.

Palacios T, Vitetta L, Coulson S, Madigan C. D, Lam Y. Y, Manuel R, Briskey D, Hendy C, Kim J, Ishoey T, Soto-Giron M, Schott E. M, Toledo G, Caterson I. 2020. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study. Nutrients 2020, 12, 2041; doi:10.3390/nu12072041.

IP RIGHTS
Title: Probiotic compositions and uses thereof for treatment of obesity-related disorders Jurisdiction: Australia Application number: 2015258769 Filing date: 12 May 2015 Status: Under examination

Specifications

Categories	Pharmaceutical Machinery & TechnologyBioavailability enhancement; Pharmaceutical PackagingDrug Delivery Systems; Finished Dosage Forms
Sales markets	Western Europe; Eastern Europe; Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Central/South America
Supplied from	Australia

More products from Medlab Clinical LTD

NanoCBD

NanoCBD is a formulation containing 16.67 mg/mL cannabidiol (CBD) as active ingredient, in a sub-micron spray applied to the oro-buccal membrane. The CBD is sourced from cannabis (hemp) strains and extracted from plant parts that produce high levels of CBD, but no THC.

IP RIGHTS:
Patent T...

More info

NanaBidial™

NanaBidial™ is an investigative new product containing 20 mg/mL of Cannabidiol (CBD) and and <1mg/mL of delta-9-tetrahydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
CLINICAL TRIAL:
The buccal administration of a NanoCelle™ CBD preparation to healthy volunteers: a ...

More info

NanoCelle® Fexodenadine

NanoCelle® Fexofenadine (as hydrochloride) is an oral-active non-sedating histamine H1-receptor antagonist.

IP RIGHTS:Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

...

More info

NanoStat™

NanoStat™ is Medlab's patented NanoCelle® delivery platform (buccal spray) for the treatment of elevated cholesterol. Atorvastatin (as calcium) belongs to the class of medicines known as “statins”, more specifically called HMG-CoA reductase inhibitors. HMG-CoA reductase is an enzyme involved in regulating cho...

More info

NanoTest™

NanoCelle® delivery platform (buccal spray) for increasing low testosterone levels in men.
IP RIGHTS:
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Tra...

More info

NanUlin™

NanoCelle® delivery platform (buccal spray) for type 2 diabetics.
IP RIGHTS:
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Transmucosal and transdermal...

More info

View all our products (10)